# KeyMed Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keymed-biosciences

- Industry: Pharmaceuticals
- Headquarters: Chengdu, China
- Website: www.keymedbio.com
- Total disclosed funding: $217M
- Latest round: Series C (Feb 10, 2021)
- Investors on record: 32

## About

KeyMed Biosciences was established in 2016, in Chengdu, China, with the main business of conducting medical researches. In 2019, the company was authorized to conduct clinic experiment for its CM310 program, a program developing drug against inflammations. In 2021, the company went public on Hong Kong Stock Exchange, stock-tickerred as 2162.HK. In 2022, its stock was included in Hong Kong Stock Connect. The company runs two production lines -- autoimmunity drugs and oncology drugs. There are ten drug developing programs undergoing, including nine of them already in the clinical-trail phase. The company is constructing the third production base in Chengdu, which will be put in use by June 2022.

## Funding rounds

- Series C, Feb 10, 2021, $130M — CPE Funds Management, Legend Star, E Fund Management Co.,Ltd, CRF Investment, Lake Bleu Capital, Hankang Capital, Fontus Capital, H&D (Singapore) Investment Holding Pte. Ltd., Chengdu Bio-town, Easy Path Ventures, Tekful Limited, Polar Grace Limited, HH KNY Holdings Limited, Jumbogood Corporation, Spring Aquila Limited, Charming Union Limited, Biofortune Investment, L.P., LAV Biosciences Fund V, L.P., Mirae Asset Growth 3 Investment Company, Orchids Limited
- Series B, Dec 10, 2019, $59M — Legend Star, SDIC Venture Capital, Hankang Capital, HH KNY Holdings Limited, Alphabio Investment Co. Ltd, Suzhou Likang Investment L.P., Jumbogood Corporation, Nanjing Jianye Sanzhengshunxin Ltd., Vantage Estate Limited, Ningbo Meishan Bonded Port Area Fengchuan Hongbo Investment Management Partnership, Hankang Biotech Fund I, L.P., LAV Biosciences Fund V, L.P.
- Series A, Jun 21, 2018, $25M — Legend Star, CDHT Hi-Tech Venture, Hankang Capital, Suzhou Jianxin Hankang Venture Capital, HH KNY Holdings Limited, Alphabio Investment Co. Ltd
- Angel, Oct 25, 2016, $2.4M — Legend Star, Xiamen Zhitou Investment Ltd., Wealth Venture Enterprises (Hong Kong) Ltd., iBridge HK Holdings Ltd.

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Angel, Series A, Series B, Series C
- Xiamen Zhitou Investment Ltd. — Angel
- Wealth Venture Enterprises (Hong Kong) Ltd. — Angel
- iBridge HK Holdings Ltd. — Angel
- CDHT Hi-Tech Venture (https://capitalatlas.ai/funds/cdht-hi-tech-venture) — Series A
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A, Series B, Series C
- Suzhou Jianxin Hankang Venture Capital — Series A
- HH KNY Holdings Limited — Series A, Series B, Series C
- Alphabio Investment Co. Ltd — Series A, Series B
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series B
- Suzhou Likang Investment L.P. — Series B
- Jumbogood Corporation — Series B, Series C
- Nanjing Jianye Sanzhengshunxin Ltd. — Series B
- Vantage Estate Limited — Series B
- Ningbo Meishan Bonded Port Area Fengchuan Hongbo Investment Management Partnership — Series B
- Hankang Biotech Fund I, L.P. — Series B
- LAV Biosciences Fund V, L.P. — Series B, Series C
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series C
- E Fund Management Co.,Ltd — Series C
- CRF Investment — Series C
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series C
- Fontus Capital (https://capitalatlas.ai/funds/fontus-capital) — Series C
- H&D (Singapore) Investment Holding Pte. Ltd. — Series C
- Chengdu Bio-town — Series C
- Easy Path Ventures — Series C
- Tekful Limited — Series C
- Polar Grace Limited — Series C
- Spring Aquila Limited — Series C
- Charming Union Limited — Series C
- Biofortune Investment, L.P. — Series C
- Mirae Asset Growth 3 Investment Company — Series C
- Orchids Limited — Series C